COMPANY CONTEXT
This profile explains business context and source coverage. It is not a verified policy impact, contract attribution, company recommendation or live exchange-security master.
WHAT THIS COMPANY DOES
Pharmaceutical products and formulations.
AUTOMATIC ISSUER EVIDENCE MONITOR
The system checks the configured official investor-relations page, archives relevant public materials, and creates reviewable evidence candidates.
Automatic issuer-document collection is a coverage mechanism. Evidence remains a draft until reviewed; it does not establish a contract, revenue effect, or investment conclusion.
CURRENT POLICY CONTEXT
STPI Tech Conclave highlights AI's Potential in Healthcare & Assistive Technologies
Evidence state: official issuer evidence matched · confidence 75/100See update context →Union Health Ministry to Observe World Mental Health Day 2026, Reaffirming Commitment to Accessible, Inclusive and People-Centred Mental Healthcare
Evidence state: official issuer evidence matched · confidence 84/100See update context →Traditional Medicine can Strengthen Preventive Healthcare & Holistic Well-Being Globally When Backed by Scientific Evidence and Quality Standards: Union Minister Shri Prataprao Jadhav
Evidence state: official issuer evidence matched · confidence 84/100See update context →SOURCE-BACKED EVIDENCE
| Source / record | What the document says | Evidence status |
|---|---|---|
| Statutory CommunicationsCompany Investor RelationsSun Pharma official investor relations ↗ | Investor Information At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns. Statutory Communications Search: 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 Intimation of Schedule of Analyst/Institutional Investor Meeting Stock Exchange Letter Disclosure of Q4FY26 Earnings Call Audio Recording Intimation of Schedule of Analyst/Institutional Investor Meeting Related Party Transactions for the half year ended 31 March 2026 Scrutinizer Report of Postal Ballot E-voting April 2026 Stock Exchange Letter – Transcript of investor call in relation to the acquisition of Organon & Co. Stock Exchange Letter Disclosure of investor call recording in relation to the acquisition of Organon & Co Audio Recording Link for the investor call in relation to the acquisition of Organon & Co. | DraftSource strength: 86/100No date recordedCollected automatically |
| Investor ContactCompany Investor RelationsSun Pharma official investor relations ↗ | Contact Us ADVERSE EVENT REPORTING Click on the tab above to report any adverse events or undesirable experience, sometimes known as side effects, associated with the use of our medicines PRODUCT QUALITY COMPLAINT REPORTING Click on the tab above to report any complaints regarding the quality of our medicines REGISTERED OFFICE Sun Pharmaceutical Industries Ltd. Sun Pharma Advanced ReCentre (SPARC), Tandalja, Vadodara – 390012, Gujarat, INDIA. Tel. : (91-265) 661 5500 Fax : (91-265) 235 4897 CORPORATE OFFICE Sun Pharmaceutical Industries Ltd. SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063 Tel. No.: (+91 22) 4324 4324 Fax No.: (+91 22) 4324 4343 BASKA SITE Sun Pharmaceutical Medicare Limited Survey No. 22 & 24, Village: Ujeti, Post : Baska, Tal. Halol-389350, Dist. Panchmahal, Gujarat, INDIA INVESTORS CONTACT Registrars & Transfer Agent: MUFG Intime India Private Limited (Previously known as Link Intime India Pvt. Ltd.) Unit: Sun Pharmaceutical Industries Limited, C 101, 247 Park, L.B.S. Marg, Vikhroli West, Mumbai (INDIA) – 400083 Tel. | DraftSource strength: 86/100No date recordedCollected automatically |
| Credit RatingCompany Investor RelationsSun Pharma official investor relations ↗ | Investor Information At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns. Credit Rating Rating Agency Instrument Type Rating ICRA Limited Long-Term/Short-Term , Fund-based/Non-fund Based Limits AAA (Stable)/ A1+ Commercial Paper A1+ CRISIL Limited Bank Facility (Short-Term) A1+ Bank Facility (Long-Term) AAA/ Stable Commercial Paper A1+ Top Important Notice As per SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023 it is mandatory for all the shareholders holding shares in physical form to update their KYC and other details. Learn More | DraftSource strength: 86/100No date recordedCollected automatically |
| Annual Reports of Subsidiary CompaniesAnnual ReportSun Pharma official investor relations ↗ | Investor Information At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns. Annual Reports of Subsidiary Companies Search: 2024-25 2023-24 2022-23 2021-22 2020-21 2019-20 2018-19 2017-18 2016-17 2015-16 2014-15 Aditya Acquisition Company Limited. Alchemee LLC Alchemee Skincare Corporation Alkaloida Chemical Company Zrt. Antibe Therapeutics Inc. AO Ranbaxy Basics GmbH Caraco Pharmaceuticals Private Limited Faststone Mercantile Company Private limited Foundation for Disease Elimination and Control of India Green Eco Development Centre Limited JSC Biosintez Neetnav Real Estate Private Limited Proactiv YK Ranbaxy (Malaysia) SDN. BHD. Ranbaxy (Poland) SP. Z.O.O Ranbaxy (Thailand) Co., Ltd. | DraftSource strength: 86/100No date recordedCollected automatically |
| Investor PresentationsInvestor PresentationSun Pharma official investor relations ↗ | Investor Information At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns. Investors Presentations 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 Investor Presentation Investor Presentation – February 2026 Investor Presentation – December 2025 Investor Presentation – August 2025 Investor Presentation – July 2025 Investor Presentation – February 2025 Investor Presentation – November 2024 Investor Presentation – September 2024 Investor Presentation – July 2024 Investor Presentation – March 2024 Investor Presentation – January 2024 Investor Presentation – September 2023 Investor Presentation – July 2023 Investor Presentation – April 2023 Investor Presentation – December 2022 Investor Presentation – September 2022 Investor Presentation – March 2022 Investor Presentation ( INR ) – June Investor Presentation ( USD ) – June Investor Presentation ( INR ) – February Investor Presentation ( USD ) – February Investor Presentation ( INR ) – November Invest… | DraftSource strength: 86/100No date recordedCollected automatically |
| Quarterly Financials, Transcripts & Earnings Call RecordingsCompany Investor RelationsSun Pharma official investor relations ↗ | Investor Information At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns. Quarterly Financials, Transcripts & Earnings Call Recordings 2025-26 Quarter 1 (Apr-Jun) Earnings Call Intimation Earnings Call Transcript Earnings Call Audio Recording Press Release Financials Quarter 2 (July- Sept) Earnings Call Intimation Earnings Call Transcript Earnings Call Audio Recording Press Release Financials Quarter 3 (Oct-Dec) Financials Press Release Earnings Call Audio Recording Earnings Call Transcript Earnings Call Intimation Quarter 4 (Jan-Mar) Financials Press Release Earnings Call Audio Recording Earnings Call Transcript Earnings Presentation Earnings Call Intimation 2024-25 Quarter 1 (Apr-Jun) Earnings Call Intimation Earnings Call Transcript Earnings Call Audio Recording Press Release Financials Quarter 2 (July- Sept) Earnings Call Intimation Earnings Call Transcript Earnings Call Audio Recording Press Release Financials Quarter 3 (Oct-Dec) Earnings Call Intimat… | DraftSource strength: 86/100No date recordedCollected automatically |
| Annual ReportsAnnual ReportSun Pharma official investor relations ↗ | Investor Information At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns. Annual Report Search: 2024 – 2025 Annual Report Download Complete Annual Report Managing Director’s Message and Management Discussion & Analysis Board’s Report and Corporate Governance Business Responsibility and Sustainability Report Standalone Financial Results Consolidated Financial Results Notice of AGM Annual Return Details Relating to the Asset Created or Acquired Through CSR Amount Spent Managing Director’s Message and Management Discussion & Analysis Board’s Report and Corporate Governance Business Responsibility Report Standalone Financial Results Consolidated Financial Results Annual Return Notice of AGM Self Declaration Format for Non-Resident Shareholders 2023 – 2024 Annual Report Download Complete Annual Report Managing Director’s Message and Management Discussion & Analysis Board’s Report and Corporate Governance Business Responsibility and Sustainability Report Standal… | DraftSource strength: 86/100No date recordedCollected automatically |
| Board Meeting & Financial ResultsCompany Investor RelationsSun Pharma official investor relations ↗ | Investor Information At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns. Board Meeting & Financial Results 2026 – 27 Quarter 1 (Apr-Jun) Closure of Trading Window 2025 – 26 Quarter 1 (Apr-Jun) Closure of Trading Window Intimation of Board Meeting Outcome of Board Meeting & Financial Results Quarter 2 (Jul-Sep) Closure of Trading Window Intimation of Board Meeting Outcome of Board Meeting & Financial Results Quarter 3 (Oct-Dec) Closure of Trading Window Intimation of Board Meeting Outcome of Board Meeting & Financial Results Quarter 4 (Jan-Mar) Closure of Trading Window Intimation of Board Meeting Outcome of Board Meeting & Financial Results 2024 – 25 Quarter 1 (Apr-Jun) Closure of Trading Window Intimation of Board Meeting Outcome of Board Meeting & Financial Results Quarter 2 (Jul-Sep) Closure of Trading Window Intimation of Board Meeting Outcome of Board Meeting & Financial Results Quarter 3 (Oct-Dec) Closure of Trading Window Intimation of Board Meetin… | DraftSource strength: 86/100No date recordedCollected automatically |